瓦尔萨坦通过调节NF-κB和MAPK通路来减弱LPS诱导的ALI
Mi Zhou1,2, Ling Meng2, Qinke He2
1Department of Respiratory and Critical Care, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Frontiers in pharmacology
|January 30, 2024
概括
在急性肺损伤 (ALI) 的小鼠模型中,瓦尔萨坦治疗改善了肺功能,减少了炎症和氧化应激. 这项研究表明,瓦尔萨坦可以通过向MAPK和NF-κB通路来成为ALI的潜在治疗剂.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 急性肺损伤 (ALI) 和急性呼吸困难综合征 (ARDS) 是严重的呼吸系统疾病,以低氧化和炎症为特征.
- 瓦尔萨坦是一种血管激素II型1受体对手,已显示出抗炎和抗氧化特性.
- 瓦尔沙坦在脂聚糖 (LPS) 诱导的ALI中的治疗潜力需要进一步研究.
研究的目的:
- 调查瓦尔沙坦对LPS诱导的ALI的保护作用.
- 阐明瓦尔萨坦在ALI中的作用的潜在机制.
主要方法:
- 在BEAS-2B细胞和小鼠中建立LPS诱导的ALI模型.
- 瓦尔萨坦的使用和肺功能,病理性肺损伤和炎症标志物的评估.
- 使用分子技术评估氧化应激,MUC5AC产生和关键信号通路 (MAPK,NF-κB).
主要成果:
- 在ALI模型中,瓦尔萨坦改善了细胞活力,肺功能,改善了肺损伤.
- 它减弱了中性粒细胞的招募,氧化应激 (增加了SOD,减少了MDA/GSSG) 和MUC5AC的过度生产.
- 瓦尔萨坦抑制了LPS诱导的NF-κB和MAPKs (P38,ERK,JNK) 的酸化.
结论:
- 瓦尔萨坦对LPS诱导的ALI具有保护作用.
- 机制包括氧化应激的减弱,MUC5AC的产生,以及通过MAPK和NF-κB通路的炎症反应.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
734
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
734
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
01:25Antihypertensive Drugs: Direct Renin Inhibitors
630
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
630
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165